XERS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Xeris Biopharma Holdings Inc (XERS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown revenue growth, its declining net income and EPS, coupled with neutral trading trends and lack of significant positive catalysts, suggest a cautious approach. The technical indicators and options data do not present a compelling entry point for long-term investment.
The MACD is slightly positive at 0.0205, but contracting, indicating weak momentum. RSI is neutral at 44.878, suggesting no clear overbought or oversold condition. Moving averages are converging, showing no strong trend. Key support is at 5.836, and resistance is at 6.328. The stock is trading near its pivot point of 6.082, indicating indecision in the market.
Revenue growth of 37.06% YoY in Q3 2025 and an improved gross margin of 81.57% (+16.60% YoY).
Net income dropped significantly by -103.95% YoY, and EPS fell to 0 (-100.00% YoY). No recent news or significant trading trends from hedge funds, insiders, or Congress. The stock has a 60% chance of a minor short-term gain (1.23% in the next day) but a potential -8.65% drop in the next month.
In Q3 2025, revenue increased to $74.38M (+37.06% YoY), but net income dropped to $621K (-103.95% YoY), and EPS fell to 0 (-100.00% YoY). Gross margin improved to 81.57% (+16.60% YoY).
No recent updates on analyst ratings or price target changes.
